ESR1 and breast cancer: Furthermore, cyclopamine inhibits the expression of ER-α, which mediates the mitogenic properties of estrogens, and acts with tamoxifen to inhibit the proliferation of steroid-responsive MCF-7 human breast cancer cells to a greater extent than either compound alone.